The digital rectal exam is no longer recommended as a routine screening tool for prostate cancer. Major medical organizations now agree that a PSA blood test is the primary screening method, and the DRE should not be used as the sole screening tool in men without symptoms. That said, the exam hasn’t disappeared from medicine. It still plays a role in specific clinical situations, just not the broad, automatic role it once had during annual physicals.
What the Guidelines Actually Say
The American Urological Association’s early detection guideline uses careful language: clinicians “may” use a DRE alongside PSA to help assess risk of clinically significant prostate cancer, but this is a conditional recommendation based on weak evidence. The guideline is explicit that there is insufficient evidence to support adding a DRE to PSA-based screening. For routine screening of men without symptoms, a PSA blood test alone is the recommended approach.
Where the DRE does earn stronger support is after an elevated PSA result has already been found. For men with a PSA level of 2 ng/mL or higher, the AUA recommends clinicians “strongly consider” a supplementary DRE to better characterize cancer risk. In that context, the exam helps determine next steps rather than serving as a first-line screening tool. One U.S. cohort study found that among men with a PSA below 4 ng/mL, only 3% with an abnormal DRE turned out to have cancer, but the DRE did improve detection of higher-grade, more aggressive disease in that group.
How Screening Has Shifted in Practice
Primary care doctors have dramatically reduced how often they perform DREs. An analysis of national survey data found that the proportion of preventive care visits where a DRE was performed dropped from 16% to about 6%, a relative decrease of 64%. PSA testing also declined by 39% over the same period. These shifts followed a 2012 recommendation from the U.S. Preventive Services Task Force that questioned the value of routine PSA screening, which had a ripple effect on DRE use as well.
The result is that many men in their 40s and 50s today have never had a DRE during a checkup, which would have been nearly unthinkable a generation ago. The exam’s role in the annual physical has largely been replaced by a periodic blood draw for PSA, with the timing and frequency depending on age and risk factors.
Who Should Still Get PSA Screening
Since PSA testing has replaced the DRE as the primary screening tool, it helps to know when that blood test is recommended. The AUA guidelines break it down by age and risk:
- Ages 40 to 45: Men at increased risk (Black men, those with certain genetic mutations, or a strong family history of prostate cancer) should be offered screening starting in this window.
- Ages 45 to 50: A baseline PSA test can be offered to men at average risk.
- Ages 50 to 69: Regular screening every 2 to 4 years is strongly recommended for this group.
These recommendations form the context in which a DRE might or might not be added. A clinician who finds an elevated PSA in a 55-year-old will likely follow up with a DRE and possibly imaging. But the DRE is no longer the starting point.
How DRE Compares to Modern Imaging
One reason the DRE has lost ground is that advanced imaging has overtaken it in accuracy. Multiparametric MRI, a detailed scan that combines several types of magnetic resonance imaging, detects advanced-stage prostate cancer far more reliably. In one study comparing the two, MRI had a sensitivity of 51% for detecting cancer that had spread beyond the prostate, compared to just 12% for DRE. MRI was also better overall at correctly classifying whether cancer had spread or remained contained, with a combined accuracy rate of 67% versus 58% for DRE.
In the UK, the National Institute for Health and Care Excellence uses DRE findings as one factor among several when helping patients decide whether to pursue MRI or biopsy, but not as a standalone screening tool. For men on active surveillance (monitoring a known low-risk cancer rather than treating it immediately), NICE recommends a DRE every 12 months as part of ongoing monitoring, performed by a urologist or specialist nurse.
Where the DRE Is Still Clinically Useful
Outside of cancer screening, the DRE remains a standard part of diagnosing several conditions. For benign prostatic hyperplasia (BPH), the enlarged prostate that causes urinary symptoms in many older men, a DRE is typically one of the first steps. The exam lets a clinician quickly assess the size and texture of the prostate, which helps guide treatment decisions.
The exam also has value for evaluating rectal and lower intestinal problems. If you notice blood in your stool, changes in bowel habits like pencil-thin stools, or difficulty passing stool, a DRE can check for physical obstructions such as tumors or other abnormalities. It often serves as an initial assessment that determines whether further testing like a colonoscopy is needed. Some providers still include it as part of a thorough annual physical, though this is increasingly a matter of individual clinical judgment rather than a blanket recommendation.
The Patient Compliance Factor
One underappreciated reason guidelines have moved away from routine DRE is that requiring the exam actually reduces screening participation. A survey of over 13,500 healthy men undergoing PSA-only screening found that only 78% said they would still participate if the screening also included a DRE. That 22% dropout rate matters at a population level. When researchers modeled the impact, PSA-only screening programs detected more cancers overall because more men showed up. Programs that required both PSA and DRE found fewer cancers and produced significantly more unnecessary biopsies.
In practical terms, a screening tool that discourages people from getting screened at all undermines the purpose of screening. This finding helped build the case for making PSA the default and reserving the DRE for targeted follow-up situations where its diagnostic value is clearer.